Category - Developments

Developments

Mateon updates Phase 1b AML data

Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid...

October 30, 2017

Developments

Asthma medicine montelukast might protect against dementia

An article published in the journal, Immunity & Aging, suggests that the leukotriene receptor antagonist, Montelukast, rejuvenates aged brains in rats. The authors of the article question whether the commonly used...

October 23, 2017

Developments

Titan Pharma presents non-clinical hypothyroidism implant data

Titan Pharmaceuticals (NASDAQ:TTNP) presented non-clinical data on the use of its ProNeura subdermal implant for the long-term, sustained delivery of liothyronine (L-T3) at the annual conference of the American Thyroid...

October 20, 2017

Developments

Echelon adds top pick status to Immunovaccine

Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11. Analyst Doug Loe...

October 12, 2017

Developments

BioTime Premvia treats first facial volume deficit patient

An investigator-led clinical trial has successfully treated its first patient in a study of BioTime’s (NYSE MKT: BTX) Premvia as a carrier for stromal vascular fraction cells (SVF) for the treatment of age-related...

October 11, 2017

Developments

Titan Pharma treats first patient with PD implant

Titan Pharmaceuticals (NASDAQ:TTNP) has treated the first patient in a Phase 1/2 trial of its ropinirole implant intended for the treatment of signs and symptoms of idiopathic Parkinson’s disease (PD). Ropinirole...

October 11, 2017

Developments

ZeptoMetrix withdraws patent claims against Microbix

Microbix Biosystems (TSX:MBX) announced the withdrawal of legal claims, alleging patent infringement, that were filed in Canadian Federal Court against Microbix by ZeptoMetrix in October 2016. The allegations by...

October 11, 2017

Developments

3DS completes stage 3 of Hodgkin’s test validation

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) completed the clinical trial component, or Stage 3, of its Hodgkin’s lymphoma (HL) test, known as Telo-HL, and has submitted the data to its statistics consulting partner...

October 10, 2017

Developments

Ortho RTi to begin trading on CSE today

Ortho Regenerative Technologies will begin trading today on the Canadian Securities Exchange under the stock symbol, ORTH. Ortho RTi is an emerging orthopedic and sports medicine technology company with a focus on novel...

October 10, 2017

Developments

Researchers create highly elastic surgical sealant

Researchers in Australia and the U.S. say they have created a highly elastic surgical glue that can quickly seal even the toughest wounds, without staples or stitches. In a paper published this week in Science...

October 6, 2017

Category - Developments

Mateon updates Phase 1b AML data

Asthma medicine montelukast might protect against dementia

Titan Pharma presents non-clinical hypothyroidism implant data

Echelon adds top pick status to Immunovaccine

BioTime Premvia treats first facial volume deficit patient

Titan Pharma treats first patient with PD implant

ZeptoMetrix withdraws patent claims against Microbix

3DS completes stage 3 of Hodgkin’s test validation

Ortho RTi to begin trading on CSE today

Researchers create highly elastic surgical sealant

General

More